Division of Medicinal and Natural Products Chemistry, University of Iowa College of Pharmacy, Iowa City, Iowa 52242, USA.
Mol Pharmacol. 2010 Sep;78(3):360-5. doi: 10.1124/mol.109.063388. Epub 2010 Jun 7.
Regulator of G protein signaling (RGS) proteins act to temporally modulate the activity of G protein subunits after G protein-coupled receptor activation. RGS proteins exert their effect by directly binding to the activated Galpha subunit of the G protein, catalyzing the accelerated hydrolysis of GTP and returning the G protein to its inactive, heterotrimeric form. In previous studies, we have sought to inhibit this GTPase-accelerating protein activity of the RGS protein by using small molecules. In this study, we investigated the mechanism of CCG-4986 [methyl-N-[(4-chlorophenyl)sulfonyl]-4-nitro-benzenesulfinimidoate], a previously reported small-molecule RGS inhibitor. Here, we find that CCG-4986 inhibits RGS4 function through the covalent modification of two spatially distinct cysteine residues on RGS4. We confirm that modification of Cys132, located near the RGS/Galpha interaction surface, modestly inhibits Galpha binding and GTPase acceleration. In addition, we report that modification of Cys148, a residue located on the opposite face of RGS4, can disrupt RGS/Galpha interaction through an allosteric mechanism that almost completely inhibits the Galpha-RGS protein-protein interaction. These findings demonstrate three important points: 1) the modification of the Cys148 allosteric site results in significant changes to the RGS interaction surface with Galpha; 2) this identifies a "hot spot" on RGS4 for binding of small molecules and triggering an allosteric change that may be significantly more effective than targeting the actual protein-protein interaction surface; and 3) because of the modification of a positional equivalent of Cys148 in RGS8 by CCG-4986, lack of inhibition indicates that RGS proteins exhibit fundamental differences in their responses to small-molecule ligands.
G 蛋白信号调节蛋白(RGS)通过与 G 蛋白偶联受体激活后 G 蛋白亚基的直接结合来发挥作用,从而调节 G 蛋白的活性。这些蛋白质通过催化 GTP 的加速水解,使 G 蛋白回到其无活性的异源三聚体形式,从而发挥作用。在以前的研究中,我们试图通过使用小分子来抑制 RGS 蛋白的这种 GTP 酶加速蛋白活性。在这项研究中,我们研究了 CCG-4986(甲基-N-[(4-氯苯基)磺酰基]-4-硝基苯磺酰亚胺)的作用机制,CCG-4986 是一种先前报道的小分子 RGS 抑制剂。在这里,我们发现 CCG-4986 通过共价修饰 RGS4 上两个空间上不同的半胱氨酸残基来抑制 RGS4 功能。我们证实,位于 RGS/Galpha 相互作用表面附近的 Cys132 的修饰可适度抑制 Galpha 结合和 GTP 酶加速。此外,我们报告说,位于 RGS4 相反面上的残基 Cys148 的修饰可以通过变构机制破坏 RGS/Galpha 相互作用,该机制几乎完全抑制 Galpha-RGS 蛋白-蛋白相互作用。这些发现表明了三个重要的观点:1)Cys148 变构位点的修饰导致 RGS 与 Galpha 的相互作用表面发生重大变化;2)这确定了 RGS4 上的“热点”,可用于小分子结合并引发变构变化,这种变化可能比靶向实际的蛋白-蛋白相互作用表面更为有效;3)由于 CCG-4986 修饰了 RGS8 中的 Cys148 位置等效物,缺乏抑制作用表明 RGS 蛋白对小分子配体的反应存在根本差异。